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Introduction
Many lifestyle-related factors contribute to cancer incidence and epidemiological studies have shown a strong link between cancer risk and diet. Indole-3 carbinol (I3C), derived from cruciferous vegetables, inhibits development of tumors of the skin, tongue, liver, colon, lung, breast and endometrium in animal models (thoroughly reviewed in (1)). It inhibits cancer development induced by carcinogens and viruses, as well as growth of spontaneous tumors. In phase II trials I3C caused significant regression of cervical intraepithelial neoplasia (CIN) (2) and was a successful treatment option for recurrent respiratory papillomatosis (3) . No adverse effects in patients have been reported. Therefore, I3C is regarded as a chemopreventive agent. However, it has been reported to exert a promoting effect when administered during the post-initiation stage of chemical carcinogenesis in rats and trout (1) .
I3C exerts several effects that may contribute to cancer prevention. It induces phase I and II enzymes in humans and animal models, leading to increased catabolism and excretion of carcinogens and cancer-promoting steroid hormones (1) . A recent phase I trial with women from a high-risk breast cancer cohort proved that I3C is safe and effective, increasing 2-hydroxylation of estradiol (4) . Efficacy in CIN treatment involved this mechanism (2) . I3C also inhibits cell proliferation and induces apoptosis in tumors in animal models (5) (6) (7) .
In cell culture, I3C modulates estradiol metabolism and significantly suppresses estrogen receptor (ERα)  signaling via a ligand-dependent mechanism (reviewed in (8) ). It also elicits anti-proliferative and pro-apoptotic responses in cancer cells, including cells refractory to steroid hormones (9) (10) (11) (12) . Two main molecular mechanisms have been suggested.
The first involves modulation of key proteins involved in cell cycle progression, e.g. CDK6, CDK2, p21Waf1/Cip1, p27Kip1, p15INK4B, cyclin D1 and cyclin E (10, 11, (13) (14) (15) (16) . Signaling through ATM and p53 has also been implicated in I3C-induced G1 arrest (17) . The second mechanism proposes Akt kinase downregulation as a pro-apoptotic event (18) (19) (20) . However a cause-effect link between Akt downregulation and I3C-induced cell death has not been established in these studies. Moreover, PI3K/Akt downregulation does not account for I3C-induced apoptosis in several cancer lines (12) .
We have shown that I3C induced downregulation of EGFR, without affecting pAkt in four breast lines (21) , although the decrease in MCF7 cells did not reach statistical significance, possibly because of the low expression level. EGFR downregulation was followed by or coincided with apoptosis via the mitochondrial pathway in MCF7, MDA-MB-468 and MDA-MB-231 cells. We also showed that MDA-MB-468 and MDA-MB-231 cells are EGFR-dependent. In MCF7 cells, I3C-induced apoptosis may be related to combined effects of I3C on ERα and EGFR. In contrast to cancer-derived cells, I3C does not induce apoptosis, but necrosis in transformed HBL100 cells. I3C-induced EGFR downregulation has been reported in prostate cancer cells PC3 (18) . For these reasons we investigated further the role of EGFR in I3C-induced events in breast cancer cells. In MDA-MB-468 cells, EGFR downregulation was preceded by increased phosphorylation of tyrosine EGFR-Y845 and coincided with increased autophosphorylation of EGFR-Y1068 (21) . Since phosphorylation of Y845 requires c-Src (22) , (23), we investigated the role of Src and tyrosine phosphorylation in I3C-induced events. We also examined expression of key proteins involved in cell cycle progression in relation to Src or EGFR activity.
Materials and Methods

Cells
Human breast cell lines MCF7, MDA-MB-468, MDA-MB-231, SKBR3 and HBL100 originating from the American Type Culture Collection were cultured as described previously (24) . This panel represents cells of four breast cancer subtypes, driven by various deregulated pathways (Supplementary Table) .
Cell viability and apoptosis-related studies
Adherent cells were estimated using the ATPlite kit (Perkin-Elmer) as described previously (21) . Cells were seeded in overnight in DMEM containing 10% FBS, followed by treatments in the same medium for 48 h. Caspase3/7 activity, as a measure of apoptosis, was determined using a Caspase-Glo 3/7 kit (Promega) as described previously (21) . Cells were seeded overnight in 10% FBS in DMEM, followed by treatments in the same medium.
Immunoblotting and immune precipitation
Preparation of cell lysates, SDS-PAGE and immunoblotting were performed as described previously (21) . Protein concentrations were measured using the Bio-Rad protein assay. Nitrocellulose filters were incubated with primary antibodies followed by secondary antibody conjugated to HRP (Dako) and detected with ECL or ECLplus (EGFR in HBL100 and MCF7 cells) reagent (Amersham). Alternatively secondary antibodies, labeled with fluorescent IR800 and IR680 dyes, were used according to the manufacturer's recommendations and detected with the Odyssey system (Li Cor, UK). Immune complexes were precipitated with protein G-beads or anti-mouse IgG-beads (Sigma) and subjected to western blotting. Protein bands on exposed films were quantified using a Syngene image system. Antibodies used in this study were against: EGFR (polyclonal sc-1005, Santa Cruz Biotechnology, UK; monoclonal R19/48, polyclonal pY845, pY1148, pY1086 and pY1068, Biosource, UK), Src (monoclonal H-12 c-Src, Santa Cruz Biotechnology, UK, monoclonal 7G9 non-pY416, polyclonal pY416 and pY527, Cell Signaling Technology, UK; polyclonal Src pY418, Santa Cruz Biotechnology, UK), phosphotyrosines (monoclonal PY20, BD Transduction Laboratories, UK; PY99, Santa Cruz Biotechnology, UK, PY100, Cell Signaling Technology), STAT-1 (monoclonal 9H2, Cell Signaling Technology, UK; polyclonal pY701, Biosource, UK), STAT-3 (monoclonal F-2, Santa Cruz Biotechnology, UK; pY705 rabbit monoclonal 58E12, Cell Signaling Technology, UK), β-actin (polyclonal, Sigma, UK), p21Cip1 (monoclonal SX118, Dako Cytomation, UK), cyclin E (monoclonal HE12, Santa Cruz Biotechnology, UK) and cyclin D1 (monoclonal DSC-6, Dako Cytomation, UK); Her2 (polyclonal 2242, Cell Signaling Technology, UK), ERα and ERβ (monoclonal F-10 and polyclonal sc-8974, Santa Cruz Biotechnology, UK), cytokeratin 5/6 (polyclonal sc-22480, Santa Cruz Biotechnology, UK).
Quantification of gene expression.
Total RNA was isolated using a Qiagen kit. cDNA was synthesized at least in duplicate for each sample using a reverse transcription kit (Promega, UK). cDNA transcribed from 50 ng of RNA was used in real-time PCR performed in an ABI 7300 thermocycler to measure the levels of mRNA for caspase-1, p21Cip1, Bcl-xL and 18S RNA using assays-ondemand gene expression kits (Applied Biosystems, UK) with Taqman probes. Levels of expression were calculated using the ΔCT method, as previously described (25) , with 18S RNA as a reference.
Cell transfection
Cells, plated (5000 cells/well) overnight in 10% FBS in DMEM, were transiently transfected with 100 ng/well of plasmid DNA using 0. 
Data analysis
Differences among the groups were analyzed using one-way ANOVA, followed by Scheffe's test to determine whether the treatment groups were different or by Dunnett's test to determine whether the treatment groups were different from a control group. The level of statistical significance was selected as P< 0.05. All data are presented as means ±SE.
Results
Expression of biomarkers of breast cancer sub-types was analyzed in a panel of cell lines ( Table) , being nondetectable in MCF7 cells in the same conditions as used for other cells (Fig. 1A-1C , small panels).
I3C modulated tyrosine phosphorylation
Since I3C induced downregulation of the receptor tyrosine kinase EGFR, we investigated whether I3C affected overall tyrosine phosphorylation. The most I3C-sensitive cells MDA-MB-468 displayed the greatest constitutive levels of tyrosine-phosphorylated proteins, possibly caused by high levels of Src and EGFR (Fig. 1B, 1C , upper panels). Increased tyrosine phosphorylation was first observed in HBL100, MDA-MB-468 and MCF7 cells after 5h of I3C treatment, while slight decrease was observed in MDA-MB-231 cells (Fig. 1B, 1C) .
The anti-phospho-tyrosine antibodies PY20 and PY99 produced different phosphorylation patterns due to differences in specificity. The major phospho-tyrosine bands about 170 kDa protein, we performed a sequential immune precipitation with anti-FAK antibodies, followed by anti-CAS antibodies (Fig. 1D) . FAK was slightly phosphorylated only in MDA-MB-468, whereas p130CAS was significantly tyrosine-phosphorylated in both I3C-treated cell lines, indicating that the 120 kDa band is more likely to be p130CAS.
Since EGFR-Y845 and p130CAS are Src substrates, we investigated whether Src was affected by I3C treatment using antibodies against activated Src (autophosphorylated on Y418), non-activated Src (non-phospho-Y418 Src) and non-activated Src in closed conformation (Src-pY529). Increased phosphorylation of Src-Y418 was observed after 5 h treatment in HBL100 (up to 350%) and MDA-MB-468 (190%) cells (Fig. 1C) . No increase was observed in MCF7 cells and phosphorylation of Src-pY418 gradually decreased to 18% after 5h in the MDA-MB-231 cells ( Fig 1C) . Taken together, these data show that I3C modulated tyrosine phosphorylation in all four breast lines.
Effect of I3C on EGFR and Src signaling in MDA-MB-468 cells
We next analyzed the sequence of events in MDA-MB-468 cells in response to I3C.
Significant increased phosphorylation of Src-Y418 occurred between 4.5-5.5 h, reaching a 6-fold maximum at 5 h (Fig 2A) . No co-incident decrease in inactive Src (non-phosphorylated Y418 or Src-pY529) was observed ( Fig. 2A) , which implied that only a small proportion became activated or activation occurred via pY529-independent mechanism (32). Activated cSrc phosphorylates EGFR on Y845 in this cell line (22) . I3C-induced phosphorylation of EGFR-Y845 was detected from 5 h, followed by increased autophosphorylation of Y1068 and Y1086 from 5.5 h (Fig. 2A) . The increases in tyrosine phosphorylation were preceded by a noticeable decrease at all three EGFR-Y sites from 3.5-5 h ( Fig. 2A) , as reported previously (21) . These events were followed by EGFR degradation from 5.5 h ( Fig. 2A) , again corresponding to our previously reported data (21) . Phosphorylated EGFR is degraded following ubiquitination (33) . In MDA-MB-468 cells, both Src and EGFR are involved in activation of STATs 1, 3 and 5, resulting in dimerization and nuclear translocation of these transcription factors (34, 35) . Increased phosphorylation of STAT-1-Y701 (preceded by a decrease) and STAT-3-Y705 was observed from 5.5 h, both increasing to 150% by 7 h ( Fig.   2A ). An insignificant decrease in phosphorylation of Akt-S473 was detected from 7 h ( Fig.   2A ). Altogether, these data indicated that I3C activated Src, which initiated a sequence of signaling involving EGFR, STAT-1 and STAT-3 in MDA-MB-468 cells.
It has been reported that Src binds to activated EGFR in MDA-MB-468 cells (36) .
Since I3C induced tyrosine phosphorylation of both Src and EGFR, we investigated if they became physically associated in response to such treatment. Indeed, EGFR was bound to immune-precipitated c-Src and, conversely, activated Src-pY418 was co-precipitated with EGFR in I3C-stimulated cells (Fig. 2B ). I3C-induced phosphorylation of Src-Y418 and Src-Y529 was significantly inhibited by the specific Src inhibitor PP2 (Fig. 2C) , both are autophosphorylation sites (37, 38) . PP2 also reduced phosphorylation of EGFR (on Srcphosphorylated Y-845 and autophosphorylated sites Y1086, Y1068 and Y1148) and STAT-1 (Fig 2C) . Phosphorylation of Akt or STAT-3 was not affected by PP2.
Effect of Src and EGFR on I3C-induced modulation of cell cycle-related proteins
We showed previously that I3C reduces EGFR levels to 30±12%, 44±22% and 31±8% at 30 h treatment in HBL100, MCF7 and MDA-MB-231 cells, respectively, while expression in MDA-MB-468 had returned to 86±9% by this time (21) (Fig 3A, 3B ). I3C has been reported to modulate p21Cip1, p27Kip1 and CDK6 in MCF7 cells and induced cell cycle arrest in MCF7 and MDA-MB-231 cells (10) . Here we investigated whether five proteins involved in cell cycle were modulated by I3C following EGFR downregulation. No such changes were found in HBL100 or MDA-MB-468 cells. Expression of p21Cip1 protein was increased in MCF7 and, particularly, in MDA-MB-231 cells after 24 h and cyclin D1 was reduced in MCF7 and MDA-MB-231 cells at 30 h (Fig. 3A, 3B) . Cyclin E was increased by I3C particularly in MCF7 cells, but the increase did not reach statistical significance (P=0.075). Preliminary experiments in MDA-MB-231 cells indicated that expression of p27Kip1 and CKD6 was also modulated by I3C (Fig. 3A) . The data on expression of p21Cip1, cyclin E and cyclin D1 in I3C-treated MCF7 cells are very similar to those, published previously, although in that study changes in cyclin E and cyclin D1 were not considered significant, when monitored in 24 hour intervals (10) . Since p21Cip1 expression can be regulated at a post-transcriptional level (39) and it is induced by I3C at a transcriptional level (11), we examined mRNA in MDA-MB-468 cells by real-time PCR. BclxL and caspase-1 were also examined, since they can also be modulated by I3C at protein and RNA levels (18, 19, 40) . We did not detect any significant change in caspase-1 or Bcl-xL gene expression (Fig. 3C) . However, p21Cip1 mRNA was significantly upregulated by I3C in MDA-MB-468 cells starting from 3 h of treatment, despite no apparent increase in protein levels (Fig. 3A) .
We next investigated whether Src or EGFR kinase activities are necessary for I3C-related modulation of cell cycle proteins and EGFR (Fig. 4) . Treatment with Src and EGFR specific inhibitors PP2 and PD153035, respectively, individually did not affect expression of proteins investigated, with the exception of p27Kip1, which was decreased to 21±7% (P< 0.05) by EGFR inhibition in MDA-MB-231 cells, and cyclin D1, which was decreased to 54±8% and 58±10% (P<0.05) by Src or EGFR inhibition, respectively, in MCF7 cells (Fig.   4A, 4B ). Regulation of cyclin D1 by EGFR in MCF7 cells is consistent with the published data (41) . In the presence of I3C expression of p21Cip1, cyclin E and p27Kip1 was increased, whereas expression of EGFR, cyclin D1 and CDK6 was decreased in both MCF7 and MDA-MB-231 cells (Fig. 4A, 4B ). Increase in cyclin E was small, particularly in MDA-MB-231 cells, but here reached statistical significance. When I3C was combined with each inhibitor, EGFR downregulation was not prevented by inhibition of either Src or EGFR activities in either cell line (Fig. 4A, 4B ). I3C-induced upregulation of p21Cip1 and cyclin E was abrogated by Src inhibition in MCF7 and MDA-MB-231 cells (Fig. 4A, 4B) . In MDA-MB-468 cells, the I3C-induced increase in p21Cip1 mRNA was reduced by Src inhibition (Fig.   4C ). I3C-induced reduction of cyclin D1 levels in MCF7 cells is likely to be a result of EGFR downregulation. The data are summarized in Fig. 8 .
Modulation of EGFR and Src influenced susceptibility to I3C
Since I3C-induced signaling involved Src and EGFR, we examined whether altered activity of these proteins could influence susceptibility to I3C. In MDA-MB-468 cells, the EGFR inhibitor PD153035 (50 nM) did not change the autophosphorylation status (Y1068) of EGFR, but increased the amounts of non-active Src (non-pY418) up to 181% (Fig. 5A ). PP2
reduced Src activation (phosphorylation of Y418) to 40% and increased amounts of nonphosphorylated Src-Y418 to 260% (Fig. 5A) . Inhibition of Src reduced EGFR autophosphorylation on Y1068 by 20% and markedly increased total EGFR up to 386% (Fig.   5A ), probably due to reduced degradation of hypo-phosphorylated EGFR (33) . These data, as well as data in Fig. 2 , indicated that Src and EGFR are inter-dependent in MDA-MB-468 cells. Pharmacological inhibition of Src and/or EGFR increased apoptosis and reduced cell viability in I3C-treated MDA-MB-468 cells (Fig. 5A) . Downregulation of Src by siRNA (50 nM) decreased amounts of total c-Src protein by half, as well as its activated form Src-pY418 and phosphorylation of EGFR-pY845 (Fig. 5B) . These changes also resulted in reduced viability of I3C-treated MDA-MB-468 cells (Fig. 5B) . Thus, downregulation of Src by siRNA or pharmacologically led to reduction in activated EGFR and increased sensitivity to I3C in MDA-MB-468 cells. Similarly, inhibition of Src or EGFR resulted in increased apoptosis in I3C-treated MDA-MB-231 cells, but did not alter viability of the other two cell lines (Fig.   5C ). Because MCF7 cells lack functional caspase-3 and HBL100 cells undergo necrosis in response to I3C (21), cell viability assays were used.
Since I3C susceptibility was enhanced by EGFR downregulation, we investigated the efficacy of combined treatment with I3C and ZD1839 (Iressa), an EGFR-specific inhibitor used in the treatment of lung cancer patients and in trials with breast cancer patients.
Although both MDA-MB-468 and MDA-MB-231 cells respond to ZD1839, only the former are sensitive to 1 μM (Fig. 6 ) in good agreement with published data on ZD1839 susceptibility of these cells (42, 43) . Combined I3C+ZD1839 treatment increased caspase 3/7 activity in MDA-MB-468 and MDA-MB-231 cells and decreased viability in these and in MCF7 cells (Fig. 6) . Hence, the combinational treatment increased death not only in MDA-MB-468 and MDA-MB-231 cells, but also in MCF7 cells, which are not sensitive to ZD1839 alone (Fig. 6) .
Finally, to confirm the involvement of Src in I3C action, we used transient overexpression of chicken wild-type Src. Since the antibody against c-Src did not recognize chicken Src, we used antibodies against Src-pY418, non-phosphorylated Src-Y418 and SrcpY529, which recognized both human and chicken Src. Overexpression of wild-type Src in MDA-MB-468 cells increased the levels of autophosphorylation of Y418 by 6 fold and nonpY418 by 2.3 fold, whereas Src-pY529 increased to 142%. Overexpression of Src also increased phosphorylation of EGFR-Y1068 by 3.2 fold and total EGFR amount by 1.6 fold compared to cells transfected with a control vector (Fig. 7A) . Similar upregulation of EGFR is reported for other transfected cell lines, overexpessing Src, due to increased c-Cbl degradation (44) . Transient overexpression of wild-type Src reduced susceptibility of MDA-MB-468 cells to I3C (Fig. 7A) . Similarly, overexpression of wild-type Src abrogated I3C-induced cell death in HBL100, but not in MDA-MB-231 or MCF7 cells (Fig. 7B) . Hence, overexpression of Src increased I3C resistance in two breast tumor cell lines. The data are summarized in Fig. 8 .
Discussion
I3C induced via tyrosine phosphorylation
The data presented here indicate that I3C modulated tyrosine phosphorylation as an early event in all cell lines, although the pattern varied in different cell lines. Phosphorylation of EGFR and, possibly, p130CAS were the most striking events in MDA-MB-468 cells and HBL100 cells, as detected by pan-phospho-tyrosine antibodies. Changes in phosphorylation of other proteins were detected only by specific antibodies. Detailed examination of I3C-induced signaling in MDA-MB-468 cells revealed that dephosphorylation of EGFR and STAT-1was followed by activation of Src, which led to EGFR activation, followed by activation of STAT-1 and STAT-3 and Erk (21) . Src-mediated signaling culminated in EGFR downregulation and the onset of apoptosis. EGFR downregulation was observed in all cell types, whereas other changes were observed only in some of them. Activation of Src and phosphorylation of p130 kDa was found in HBL100 cells. Phosphorylation of protein similar in molecular weight to EGFR was detected in MCF7 cells. Tyrosine dephosphorylation was detected in MDA-MB-231 cells. Elements of this signaling have been reported in other models. EGFR dephosphorylation prior to activation has been observed (21) . I3C was shown to decrease tyrosine phosphorylation in the liver in rats while inhibiting the development of preneoplastic lesions in a carcinogen-induced hepatocarcinogenesis model (45) . STAT-1 has been implicated in a combined response to I3C and interferon in MCF7 cells (46) .
The role of EGFR in I3C-induced cell death
Several lines of evidence indicate that EGFR downregulation is responsible for I3C-induced apoptosis. Firstly, it is the only common event so far detected in I3C-treated cells (21) . Secondly, the timescale of I3C-induced reduction in EGFR levels in breast cancer cell lines was inversely related to susceptibility, i.e. after 6 h in the most I3C-susceptible MDA-MB-468 cells and after 24-30 h in other cells (21) . Thirdly, EGFR inhibitors PD153035 or ZD1839 increased I3C-induced cell death in all breast cancer cell lines, but not HBL100. In contrast to other breast cancer cells or normal fibroblasts, the ER-negative HBL100 cells are entirely insensitive to downregulation of EGFR and do not undergo apoptosis in the presence of I3C (21) . Published data indicate these cells require bFGF, which they secrete, whereas the other cells require EGFR ligands for growth (Supplementary Table) . The HBL100 cells can be sensitized to I3C by blocking protein synthesis during treatment (21) , which would inhibit (Fig. 6 ). The effect of EGFR inhibition on viability of ERα-positive MCF7 cells is small (21) . Neither I3C (50, 100 μM) nor 1 μM ZD1839 inhibited these cells; however, in combination, they reduced viability. At higher doses, I3C-induced apoptosis in MFC7 cells is likely to be caused by combined I3C effect on ERα and EGFR.
The role of Src-EGFR interactions in response to I3C
Src became physically associated with activated EGFR in I3C-treated MDA-MB-468 cells and modulation of either affected the other partner in the complex (Fig. 2C, 5A , 5B, 7A).
In untreated MDA-MB-231 cells, EGFR-Y845 phosphorylation was not detectable, even though Src was active and EGFR-Y1068 was markedly phosphorylated (Fig. 1B) . Src-EGFR interactions are less significant in cells with low receptor expression (36) . Besides transactivation, Src is involved in other aspects of EGFR signaling by regulating the basal levels of EGFR via internalization and degradation via phosphorylation of dynamin, clathrin and Cbl (47) . In agreement with this, Src modulated basal EGFR levels, as well as activation (Fig. 5A, 7A ). Src also couples EGFR to G-protein-coupled receptors and adhesion receptors, 
Roles of Src and EGFR in I3C-modulation of cell cycle-related proteins
I3C has been reported to modulate cell cycle-related proteins, p21Cip1, p27Kip1 and CDK6, in MCF7 cells and induced cell cycle arrest in MCF7 and MDA-MB-231 cells (10) .
Moreover, it activates transcription of p21Cip1 in prostate cancer PC3 cells (11) . Here I3C induced upregulation of p21Cip1, p27Kip1 and cyclin E and downregulation of CDK6 and cyclin D1 not only in MCF7, but also in MDA-MB-231. Recently I3C-induced p21Cip1 upregulation has been related to p53 function (17) in contradiction to I3C-induced p21Cip1 increase in p53 mutant or p53-null cells (11, 17) . Our data also indicate that p21Cip1protein or mRNA upregulation occurred in p53-mutant MDA-MB-231 and MDA-MB-468 cells, respectively (Supplementary Table) and cyclin E is essential to I3C action, generating a cytoplasmic inactive p21Cip1-cyclin E-CDK2-75kDa complex (16) . I3C-induced downregulation of cyclin D1 levels in MCF7 cells is likely to be a result of EGFR downregulation, since EGFR inhibition by PD153035 also resulted in decreased cyclin D1 in these cells. EGFR signaling and nuclear EGFR in particular have been implicated in cyclin D1 expression (41,52). Thus, both Src and EGFR are involved in I3C-induced cell cycle arrest.
Importantly I3C-induced modulation of cell cycle-related proteins occurred after 24-30 hour-treatment, whereas loss of mitochondrial potential was initiated by 16 hour-treatment in MCF7 cells and phosphatidylserine externalization was detected in MDA-MB-231 cells after 24 hour-treatment (21) . Therefore, the onset of apoptosis preceded or coincided with the cell cycle arrest-related changes. p21Cip1 is implicated in apoptosis, as well as in cell cycle arrest (39) . In agreement with this, p21Cip1 induction was reported during apoptosis induced by EGFR downregulation by ZD1839 in MDA-MB-231 cells (43) . Downregulation by PD153035 did not lead to increased p21Cip1 in MDA-MB-231 cells in this study, possibly, because we used a much less potent dose to avoid apoptotic events. In MDA-MB-468 cells, EGFR activation by EGF results in apoptosis (53), which is mediated by STAT-1 and involves upregulation of p21Cip1 and caspase activity (54,55). We found some differences between apoptosis induced by I3C and EGF. The upregulation of p21Cip1 mRNA occurred before activation of STAT-1 (compare Fig. 2A and 3C ).
In conclusion, the data presented here implicate Src, EGFR and tyrosine phosphorylation in the I3C-induced response in three breast cancer subtypes. However, further investigations are required to determine the primary target of I3C action. Importantly, our data show for the first time that involvement of EGFR and Src is essential to I3C action.
They indicate that the apoptosis and cell cycle arrest observed after I3C treatment share some common signaling pathways related to Src and/or EGFR activity, and the impact on cancer 
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Fig. 2. I3C-induced signaling in MDA-MB-468 cells involved Src and EGFR.
A. MDA-MB-468 cells were treated with 125 μM I3C for 3.5-7 hours. Western blots were developed with antibodies shown. B-C. MDA-MB-468 cells were treated with 125 μM I3C and 10 μM PP2 (C) for 5 h. Western blots were developed with the antibodies indicated.
Proteins were analyzed in whole cell extract (C) or immune-precipitated with either anti-c-Src or anti-EGFR antibodies (B). 
